CD19 and B-cell non-Hodgkin lymphoma: Moreover, the exploration of multi-targeted CAR-T cells has been undertaken, with preclinical studies showcasing the swift elimination of B cell lymphoma using tri-specific CD19-CD20-CD22-targeting CAR-T cells (50).